Bavarian Nordic stock soars over 15% as WHO declares Mpox a global health emergency

August 15, 2024 10:18 AM PDT | By Invezz
 Bavarian Nordic stock soars over 15% as WHO declares Mpox a global health emergency
Image source: Invezz

Shares of Bavarian Nordic, a Danish vaccine manufacturer, surged over 15% on Thursday following the World Health Organization’s (WHO) declaration of Mpox as a public health emergency.

This announcement has drawn significant attention to the Hellerup-based company, which, alongside Emergent BioSolutions Inc., is one of the only two firms with a vaccine endorsed by the Centers for Disease Control and Prevention (CDC) for combating the Mpox (also known as monkeypox) virus.

Emergent BioSolutions also saw a stock rise of over 10% in response.

The WHO’s declaration reverberated globally, particularly impacting Tokyo-based Precision System Science Co., which focuses on vaccine commercialization, with its shares skyrocketing 40% on the same day.

Can Bavarian Nordic meet the rising demand?

In response to the heightened demand, Bavarian Nordic has assured that it can ramp up production to meet the urgent need for Mpox vaccines.

CEO Paul Chaplin confirmed that the company is prepared to supply up to 2 million doses by the end of this year and has plans to increase production to 10 million doses by the end of 2025.

However, he emphasized the need for swift action from global health authorities: “We have the capacity, but we need people to start placing orders pretty fast.”

Currently, Wall Street analysts maintain an “overweight” rating on Bavarian Nordic stock, reflecting optimism about the company’s ability to scale its operations and meet global demand.

Challenges over vaccine access remain

Despite Bavarian Nordic’s reassurances, concerns about vaccine availability and distribution remain. 

Brian Ferguson, an associate professor at the University of Cambridge, expressed skepticism regarding the global supply of Mpox vaccines, particularly in light of the recent outbreak in Congo that has already spread to neighboring countries. 

“Access to the available vaccines is a significant concern,” Ferguson noted, “as they are not getting to where they are needed.”

The WHO’s designation of Mpox as a “public health emergency of international concern” underscores the severity of the outbreak, calling for accelerated measures to contain the virus. 

The organization is actively collaborating with affected countries to ensure vaccine distribution, but challenges persist. 

Jimmy Whitworth, an emeritus professor at the London School of Hygiene and Tropical Medicine, highlighted the potential obstacles, stating that “cost and availability of the vaccine will be a significant challenge.”

Whitworth estimated that around 10 million doses would be necessary to control the current outbreak, emphasizing the urgency of the situation.

While the WHO’s declaration has brought renewed focus and urgency to the situation, questions about vaccine access and distribution remain unresolved. 

For investors, Bavarian Nordic’s ability to scale production and navigate these challenges will be critical in determining the company’s future performance in the market.

The post Bavarian Nordic stock soars over 15% as WHO declares Mpox a global health emergency appeared first on Invezz


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next